Single daily dose of cyclosporine in patients with primary glomerulonephritis and nephrotic syndrome

Clinical Nephrology

Volumn 67, Issue 5, 2007, Pages 285-292

  Rasche, F M ^a   Keller, F ^a   Kunze, G ^a   Boesler, B ^a   Czock, D ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Cyclosporine; Glomerulonephritis; Nephrotic syndrome; Nephrotoxity; Pharmacokinetics; Proteinuria; Side effects

Indexed keywords

BENAZEPRIL; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PLASMA PROTEIN; PREDNISOLONE; RAMIPRIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAINTENANCE THERAPY; MALE; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; PROTEINURIA; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 34248546382     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP67285     Document Type: Article

References (22)

1. Calis L, Vila A, Carrera M, Nieto J. Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int. 1999; 55: 1051-1056.
2. Calo L, Giacon B, Davis PA, Pagnin E, Piccin A, Riegler P, Huber W, Antonello A, Semplicini A. Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of canvedilol and nifedipine. Clin Nephrol. 2002; 58: 103-110.
3. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999; 56: 2220-2226.
4. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001; 59: 1484-1490.
5. Chishti AS, Sorof JM, Brewer ED, Kale AS. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis. 2001; 38: 754-760.
6. Cole E, Maham N, Cardella C, Cattran D, Fenton S, Hamel J, O'Grady C, Smith R. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation. 2003; 75: 2086-2090.
7. Einecke G, Mai I, Fritsche L, Slowinski T, Waiser J, Glander P, Bohler T, Neumayer HH, Budde K. Cyclosporin C 2-hour monitoring after renal transplantation. Int J Clin Pharmacol Ther. 2003; 41: 477-481.
8. Ingulli E, Tejani A. Focal segmental glomerulosclerosis in children. Curr Opin Pediatr. 1995; 7: 176-181. Mahalati K, Belitsky P, Sketris I. West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999; 68: 55-62.
9. Mahalati K, Lawen J, Kiberd B, Belitsky P. Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period? J Urol. 2000; 163: 37-41.
10. Mason J. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr Nephrol. 1990; 4: 686-704.
11. Meyrier A, Noel LH, Auriche P, Collard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societé de Nephrologie. Kidney Int. 1994; 45: 1446-1456.
12. Nakahata T, Tanaka H, Tsugawa K, Suzuki K, Ito E, Waga S. C1-C2 point monitoring of low-dose cyclosporin A given as a single daily dose in children with steroid-dependent relapsing nephrotic syndrome. Clin Nephrol. 2005; 64: 258-263.
13. Ponticelli C, Passerini P. The place of cyclosprine in the management of primary nephrotic syndrome. Bio Drugs. 1999; 12: 327-341.
14. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993; 43: 1377-1384.
15. Primmett DR, Levine M, Kovarik JM, Mueller EA, Keown PA. Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther Drug Monit. 1998; 20: 276-283.
16. Rowland M, Tozer T. Clinical pharmacokinetics. Concepts and applications (3rd ed). Pennsylvania: Lippincott, Williams and Wilkins; 1995. pp. 459-463.
17. Ryffel B. The carcinogenicity of cyclosporin. Toxicology. 1992; 73: 1-22.
18. Schadeli F, Marti HP, Frey FJ, Uehlinger DE. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. Clin Pharmacokinet. 2002; 41: 59-69.
19. Schuetz M, Einecke G, Mail I, Neumayer HH, Glander P, Waiser J, Fritsche L, Budde K. Problems of cyclosporine absorption profiling using C2-monitoring. Eur J Med Res. 2005; 10: 175-178.
20. Sijpkens YW, Mallat MJ, Siegert CE, Zwinderman AH, Westendorp RG, de Fijter JW, van Es LA, Paul LC. Risk factors of cyclosporine nephrotoxicity after conversion from Sandimmune to Neoral. Clin Nephrol. 2001; 55: 149-155.
21. Tanaka H, Nakahata T, Ito E. Single-dose daily administration of cyclosporin A for relapsing nephrotic syndrome. Pediatr Nephrol. 2004; 19: 1055-1058.
22. Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardo LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP et al. Clinical outcomes during the first three months post transplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation. 2003; 76: 903-908.